MedTrace Logo

ATHN 7: Hemophilia Natural History Study

NCT03619863 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 395

Last updated 2025-02-12

No results posted yet for this study

Summary

This is a real-world study of the safety of the treatments used for people with hemophilia. The study will follow people with hemophilia A or B from across the country for about 4 years as they receive treatment. The hemophilia treatment center (HTC) physician and participant will decide on the FDA-approved treatment to be used which may include non-factor products, bypassing agents, or clotting factor replacement products. The goal of this research is to study the use of hemophilia treatment products and their outcomes.

Conditions

  • Hemophilia A With Inhibitor
  • Haemophilia A Without Inhibitor
  • Hemophilia B With Inhibitor
  • Haemophilia B Without Inhibitor

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • American Thrombosis and Hemostasis Network

    lead NETWORK

Principal Investigators

  • Tyler Buckner, MD, MSc · Hemophilia and Thrombosis Center/ University of Colorado Anschutz Medical Campus

  • Michael Recht, MD, PhD · The Hemophilia Center at Oregon Health & Science University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-24
Primary Completion
2023-05-31
Completion
2024-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03619863 on ClinicalTrials.gov